Caribou Biosciences, Inc. Operating Expenses
Caribou Biosciences, Inc. (CRBU) reported Operating Expenses of $26.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Caribou Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $26.84M, a 46.59% decline year-over-year.
- Caribou Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $28.68M, a 36.65% decline year-over-year.
- Caribou Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $32.39M, a 20.90% decline year-over-year.
- Caribou Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $31.60M, a 21.52% decline year-over-year.
- Caribou Biosciences, Inc. operating expenses for fiscal 2025 was $159.50M, a 9.69% decline from fiscal 2024.
- Caribou Biosciences, Inc. operating expenses for fiscal 2024 was $176.61M, a 17.32% increase from fiscal 2023.
- Caribou Biosciences, Inc. operating expenses for fiscal 2023 was $150.54M, a 25.19% increase from fiscal 2022.
- Caribou Biosciences, Inc. operating expenses for fiscal 2022 was $120.25M, a 57.03% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.84M 10-Q · filed 2026-08-13 | $55.52M 10-Q · filed 2026-08-13 | $87.91M derived: sum of 3 quarters · filed 2026-08-13 | $119.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $28.68M 10-Q · filed 2026-05-07 | $61.07M derived: sum of 2 quarters · filed 2026-05-07 | $92.67M derived: sum of 3 quarters · filed 2026-05-07 | $142.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $32.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $63.99M derived: sum of 2 quarters · filed 2026-03-05 | $114.24M derived: sum of 3 quarters · filed 2026-08-13 | $159.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $31.60M 10-Q · filed 2025-11-12 | $81.84M derived: sum of 2 quarters · filed 2026-08-13 | $127.11M 10-Q · filed 2025-11-12 | $168.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $50.24M 10-Q · filed 2026-08-13 | $95.51M 10-Q · filed 2026-08-13 | $136.46M derived: sum of 3 quarters · filed 2026-08-13 | $176.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $45.27M 10-Q · filed 2026-05-07 | $86.22M derived: sum of 2 quarters · filed 2026-05-07 | $126.48M derived: sum of 3 quarters · filed 2026-05-07 | $173.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $40.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $81.21M derived: sum of 2 quarters · filed 2026-03-05 | $128.18M derived: sum of 3 quarters · filed 2026-03-05 | $176.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $40.26M 10-Q · filed 2025-11-12 | $87.23M derived: sum of 2 quarters · filed 2025-11-12 | $135.66M 10-Q · filed 2025-11-12 | $176.66M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $46.97M 10-Q · filed 2025-08-12 | $95.40M 10-Q · filed 2025-08-12 | $136.40M derived: sum of 3 quarters · filed 2025-08-12 | $174.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $48.43M 10-Q · filed 2025-05-08 | $89.43M derived: sum of 2 quarters · filed 2025-05-08 | $127.73M derived: sum of 3 quarters · filed 2025-05-08 | $164.35M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $79.30M derived: sum of 2 quarters · filed 2025-03-10 | $115.92M derived: sum of 3 quarters · filed 2025-03-10 | $150.54M 10-K · filed 2025-03-10 |
| 2023-09-30 | $38.30M 10-Q · filed 2024-11-06 | $74.92M derived: sum of 2 quarters · filed 2024-11-06 | $109.54M 10-Q · filed 2024-11-06 | $143.81M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $36.62M 10-Q · filed 2024-08-06 | $71.24M 10-Q · filed 2024-08-06 | $105.51M derived: sum of 3 quarters · filed 2024-08-06 | $135.35M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $34.62M 10-Q · filed 2024-05-07 | $68.89M derived: sum of 2 quarters · filed 2024-05-07 | $98.73M derived: sum of 3 quarters · filed 2024-05-07 | $131.35M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $64.11M derived: sum of 2 quarters · filed 2024-03-11 | $96.73M derived: sum of 3 quarters · filed 2024-03-11 | $120.25M 10-K · filed 2024-03-11 |
| 2022-09-30 | $29.84M 10-Q · filed 2023-11-07 | $62.46M derived: sum of 2 quarters · filed 2023-11-07 | $85.98M 10-Q · filed 2023-11-07 | $108.94M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $32.62M 10-Q · filed 2023-08-08 | $56.14M 10-Q · filed 2023-08-08 | $79.10M derived: sum of 3 quarters · filed 2023-08-08 | $101.70M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $23.52M 10-Q · filed 2023-05-09 | $46.48M derived: sum of 2 quarters · filed 2023-05-09 | $69.07M derived: sum of 3 quarters · filed 2023-05-09 | $86.51M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $22.96M 10-K · filed 2022-03-21 | $45.56M derived: sum of 2 quarters · filed 2022-11-08 | $63.00M derived: sum of 3 quarters · filed 2022-11-08 | $76.58M 10-K · filed 2023-03-09 |
| 2021-09-30 | $22.59M 10-Q · filed 2022-11-08 | $40.03M derived: sum of 2 quarters · filed 2022-11-08 | $53.61M 10-Q · filed 2022-11-08 | $70.99M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $17.44M 10-Q · filed 2022-08-09 | $32.20M 10-Q · filed 2021-09-02 | $48.40M derived: sum of 3 quarters · filed 2022-08-09 | $57.82M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $14.76M 10-Q · filed 2022-05-09 | $30.96M derived: sum of 2 quarters · filed 2022-05-09 | $40.38M derived: sum of 3 quarters · filed 2022-05-09 | $51.12M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $16.20M 10-K · filed 2022-03-21 | $25.62M derived: sum of 2 quarters · filed 2022-03-21 | $36.35M derived: sum of 3 quarters · filed 2022-03-21 | $48.48M 10-K · filed 2022-03-21 |
| 2020-09-30 | $9.43M 10-K · filed 2022-03-21 | $20.16M derived: sum of 2 quarters · filed 2022-03-21 | $32.29M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $10.73M 10-K · filed 2022-03-21 | $22.86M 10-Q · filed 2021-09-02 | ||
| 2020-03-31 | $12.13M 10-K · filed 2022-03-21 | |||
| 2019-12-31 | $40.09M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |